Cargando…
Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA
The presence of neutralizing antibodies (NAbs) against SARS-CoV-2 represent a surrogate marker of immunologic protection in populations at high risk of infection such as healthcare workers caring for hospitalized patients with COVID-19. As recommended by CDC and the European CDC, the use of rapid di...
Autores principales: | Tuells, José, Parra-Grande, Mónica, Santos-Calle, Francisco J., Montagud, Ana C., Egoavil, Cecilia M., García-Rivera, Celia, Caballero, Pablo, Gabaldón-Bravo, Eva M., Rodríguez-Diaz, Juan Carlos, Hurtado-Sánchez, José Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032347/ https://www.ncbi.nlm.nih.gov/pubmed/35455259 http://dx.doi.org/10.3390/vaccines10040510 |
Ejemplares similares
-
Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)
por: Meyer, Benjamin, et al.
Publicado: (2020) -
Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)
por: Winichakoon, Poramed, et al.
Publicado: (2023) -
Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain)
por: Tuells, Jose, et al.
Publicado: (2021) -
Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination()
por: Pezzati, Laura, et al.
Publicado: (2023) -
Trends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community—Spain (2008–2018)
por: Egoavil, Cecilia M., et al.
Publicado: (2020)